Dr Agarwals Eye Hospital Ltd
Dr Agarwal's Eye Hospital Ltd is a leading chain of eye hospitals with predominant presence in Tamil Nadu.[1]
- Market Cap ₹ 2,292 Cr.
- Current Price ₹ 4,743
- High / Low ₹ 6,392 / 3,513
- Stock P/E 32.8
- Book Value ₹ 651
- Dividend Yield 0.13 %
- ROCE 17.5 %
- ROE 29.5 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 32.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.2%
Cons
- Stock is trading at 7.29 times its book value
- Company might be capitalizing the interest cost
- Promoters have pledged 29.3% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare BSE Allcap
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113 | 118 | 137 | 149 | 153 | 170 | 176 | 140 | 201 | 268 | 319 | 397 | 451 | |
| 102 | 103 | 119 | 126 | 129 | 140 | 129 | 109 | 143 | 192 | 227 | 277 | 308 | |
| Operating Profit | 11 | 15 | 18 | 23 | 24 | 30 | 47 | 31 | 59 | 76 | 92 | 120 | 143 |
| OPM % | 9% | 13% | 13% | 15% | 16% | 18% | 27% | 22% | 29% | 28% | 29% | 30% | 32% |
| 3 | 0 | -5 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 5 | 5 | 4 | |
| Interest | 4 | 4 | 5 | 4 | 3 | 4 | 9 | 7 | 7 | 8 | 8 | 15 | 13 |
| Depreciation | 6 | 6 | 9 | 9 | 10 | 11 | 21 | 19 | 20 | 20 | 27 | 39 | 44 |
| Profit before tax | 4 | 5 | -0 | 11 | 13 | 17 | 20 | 6 | 32 | 49 | 62 | 71 | 91 |
| Tax % | 35% | -6% | -104% | 33% | 49% | 32% | 31% | 125% | 25% | 25% | 26% | 23% | |
| 2 | 6 | 0 | 7 | 7 | 12 | 14 | -1 | 24 | 37 | 46 | 55 | 70 | |
| EPS in Rs | 5.17 | 12.13 | 0.09 | 15.62 | 14.43 | 25.36 | 29.11 | -3.06 | 51.28 | 78.55 | 98.64 | 116.28 | 146.48 |
| Dividend Payout % | 23% | 10% | 940% | 10% | 8% | 6% | 0% | 0% | 6% | 4% | 3% | 5% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 18% |
| 3 Years: | 25% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 32% |
| 3 Years: | 31% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 66% |
| 3 Years: | 70% |
| 1 Year: | 17% |
| Return on Equity | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 30% |
| 3 Years: | 33% |
| Last Year: | 30% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 14 | 19 | 19 | 25 | 30 | 41 | 51 | 50 | 73 | 109 | 152 | 205 | 310 |
| 28 | 27 | 31 | 23 | 18 | 24 | 60 | 68 | 193 | 232 | 268 | 333 | 335 | |
| 20 | 18 | 24 | 20 | 28 | 31 | 24 | 33 | 42 | 44 | 71 | 71 | 79 | |
| Total Liabilities | 67 | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 | 729 |
| 26 | 26 | 34 | 33 | 36 | 55 | 94 | 96 | 214 | 260 | 316 | 393 | 409 | |
| CWIP | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 26 | 62 | 97 | 128 | 157 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 85 |
| 41 | 43 | 44 | 38 | 42 | 45 | 47 | 60 | 73 | 67 | 83 | 80 | 79 | |
| Total Assets | 67 | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 | 729 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12 | 14 | 17 | 20 | 19 | 25 | 39 | 34 | 57 | 70 | 90 | 94 | |
| -11 | -10 | -17 | -8 | -11 | -25 | -17 | -11 | -46 | -71 | -70 | -133 | |
| -3 | -5 | -0 | -12 | -8 | 2 | -20 | -8 | -4 | 0 | -14 | 17 | |
| Net Cash Flow | -2 | -1 | 0 | 0 | -0 | 2 | 2 | 15 | 7 | -1 | 6 | -22 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 19 | 19 | 24 | 16 | 17 | 19 | 14 | 23 | 16 | 14 | 15 | 13 |
| Inventory Days | 96 | 238 | 200 | 123 | 148 | 124 | 132 | 117 | 91 | 73 | 106 | 117 |
| Days Payable | 137 | 360 | 371 | 277 | 353 | 292 | 224 | 401 | 410 | 327 | 345 | 263 |
| Cash Conversion Cycle | -22 | -103 | -146 | -138 | -189 | -149 | -78 | -260 | -303 | -240 | -224 | -133 |
| Working Capital Days | -52 | -31 | -39 | -25 | -39 | -22 | -34 | -70 | -58 | -50 | -63 | -51 |
| ROCE % | 17% | 19% | 18% | 29% | 32% | 34% | 30% | 11% | 20% | 19% | 18% | 18% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Registered Office Address
3 Feb - Unaudited Q3/9M FY26 results: 9M revenue Rs350.9cr, PAT Rs53.9cr; registered office shifted Feb 5, 2026.
-
Results- Financial Results For The Quarter And Nine Months Ended December 31, 2025
3 Feb - Approved unaudited results to Dec 31, 2025; registered office shifted effective Feb 05, 2026.
-
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025
3 Feb - Unaudited Q3/9M results: 9M profit ₹53.86Cr; registered office shift effective Feb 05, 2026.
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2025
28 Jan - Board meeting Feb 03, 2026 approves unaudited results quarter and nine months ended Dec 31, 2025; trading window closed.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Jan
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2025TranscriptAI SummaryPPT
History[1]
Incorporated in 1994, is a leading eye care services chain with a predominant presence in Tamil Nadu. AEHL offers comprehensive eye care services through a network of 63 facilities, supported by a team of over 230 doctors. Company operates as a subsidiary of Dr. Agarwal’s Health Care Limited, which holds a 71.9% stake.